Capricor Therapeutics, Inc.CAPRNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR+4.3%
5Y CAGR+1.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+4.3%/yr
vs +49.7%/yr prior
5Y CAGR
+1.4%/yr
Consistent
Acceleration
-45.4pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 69.02% |
| 2024 | 37.10% |
| 2023 | 67.06% |
| 2022 | 60.76% |
| 2021 | 60.47% |
| 2020 | 64.48% |
| 2019 | -57.39% |
| 2018 | 12.08% |
| 2017 | -32.89% |
| 2016 | 16.61% |